SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

SMS Pharmaceuticals surges on eyeing demerger of Non-FDA Manufacturing Units

09 Feb 2015 Evaluate

SMS Pharmaceuticals is currently trading at Rs. 485.00, up by 12.50 points or 2.65% from its previous closing of Rs. 472.50 on the BSE.

The scrip opened at Rs. 474.50 and has touched a high and low of Rs. 505.00 and Rs. 474.50 respectively. So far 14692 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 585.00 on 23-Sep-2014 and a 52 week low of Rs. 190.50 on 06-Feb-2014.

Last one week high and low of the scrip stood at Rs. 516.85 and Rs. 463.20 respectively. The current market cap of the company is Rs. 408.02 crore.

The promoters holding in the company stood at 63.91%, while Institutions and Non-Institutions held 0.42% and 35.66% respectively.

SMS Pharmaceuticals has received an approval for appointment of an Independent Committee to explore the possibilities of demerger of Non-FDA Manufacturing Units of the company. The board of directors at their meeting held on February 06, 2015 have approved for the same.

SMS Pharmaceuticals is a global player in API manufacturing having strong research and manufacturing team supported by state of art facilities. The company is diversifying into CRAMS by creating research and manufacturing facilities bettering the requirements of the regulatory markets to appeal to international clientele.

 

SMS Pharmaceuticals Share Price

427.60 3.45 (0.81%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×